Menu
Logo

SIGNIFICANT IMPROVEMENT IN 7 OF 8 QUALITY OF LIFE DOMAINS versus placebo

1_3.png



2_6.png

3_5.png


*SERAPHIN was a multicenter, double-blind, placebo-controlled, longterm, event-driven, phase III trial of macitentan in patients with PAH to evaluate the effect of macitentan on HRQoL in patients with PAH in the Study with an Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension after 6 months, 12 months and at the end of treatment to Improve Clinical Outcome. 710 patients were included in this
analysis and received placebo, macitentan 3 mg, or macitentan 10 mg. (p<0.05) PF: Physical functioning; RP: Role physical; BP: Bodily pain; GH: General health; VT: Vitality;
SF: Social functioning; RE: Role-emotional; MH: Mental health

Significant increase in 6MWDa at 6 months compared to placebo

5_2.png


aThe change from baseline to month 6 in the 6-minute walk distance was evaluated as prespecified secondary end points.
bMean change versus placebo
6MWD: 6-minute walk distance

REFERENCES:
1. Mehta S, Sastry BKS, Souza R, et al. Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial. Chest. 2017; 151 (1): 106-118.

2. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. NEngl J Med. 2013; 369 (9): 809-18.

CP-250196

opsumit_footer.png